Literature DB >> 11685739

Imaging of hepatocellular carcinoma: a practical approach.

F V Coakley1, L H Schwartz.   

Abstract

Imaging of hepatocellular carcinoma (HCC) is complicated because the tumor has a varied radiologic appearance and frequently coexists with cirrhotic regenerative and dysplastic nodules. In cirrhotic patients, any dominant solid nodule that is not clearly a hemangioma should be considered a HCC until proven otherwise, especially if the lesion is hypervascular, of high T2 signal intensity, or demonstrates venous invasion. Biopsy of HCC in cirrhosis is risky and surveillance is often preferable. The doubling time of HCC is 1 to 12 months, and a nodule that is stable over 4 months is very unlikely to be a HCC. However, stable nodules cannot be dismissed, since livers containing dysplastic nodules are at high risk to develop HCC. In noncirrhotic patients, any solid mass that is not clearly a hemangioma or focal nodular hyperplasia is potentially a HCC, and biopsy may be required. Venous invasion by tumor should be distinguished from bland thrombus. Imaging detection of nodal metastases is limited by the frequent finding of benign reactive lymphadenopathy in cirrhosis. Resection is the preferred treatment for HCC, but is contraindicated in the presence of tumors in both lobes, major venous invasion, invasion of adjacent organs other than the gallbladder, tumor rupture, nodal metastases, or distant metastases. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Year:  2001        PMID: 11685739     DOI: 10.1016/s0093-7754(01)90139-3

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  9 in total

1.  Etiology and management of hemmorrhage in spontaneous liver rupture: a report of 70 cases.

Authors:  Zhe-Yu Chen; Qing-Hui Qi; Zuo-Liang Dong
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

2.  Endoscopic Ultrasound -guided Fine-Needle Aspiration of a Portal Vein Thrombus to Aid in the Diagnosis and Staging of Hepatocellular Carcinoma.

Authors:  Hazar Michael; Christopher Lenza; Mala Gupta; Douglas S Katz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

3.  Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy.

Authors:  Tyler D Fields; Prejesh Philips; Charles R Scoggins; Cliff Tatum; Lawrence Kelly; Kelly M McMasters; Robert C G Martin
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

Review 4.  Characteristics of common solid liver lesions and recommendations for diagnostic workup.

Authors:  Nimer Assy; Gattas Nasser; Agness Djibre; Zaza Beniashvili; Saad Elias; Jamal Zidan
Journal:  World J Gastroenterol       Date:  2009-07-14       Impact factor: 5.742

Review 5.  Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.

Authors:  Bieke Lambert; Christophe Van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08       Impact factor: 9.236

6.  Double contrast-enhanced two-dimensional and three-dimensional ultrasonography for evaluation of gastric lesions.

Authors:  Hong Shi; Xiu-Hua Yu; Xin-Zhang Guo; Yuan Guo; Hong Zhang; Bin Qian; Zhang-Rui Wei; Li Li; Xian-Chen Wang; Zi-Xiang Kong
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

Review 7.  Hepatocellular carcinoma and other malignancies in autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2013-01-10       Impact factor: 3.199

8.  Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions.

Authors:  Li Huo; Jinxia Guo; Yonghong Dang; Jinqiao Lv; Youjing Zheng; Fang Li; Qingguo Xie; Xiaoyuan Chen
Journal:  Theranostics       Date:  2015-01-21       Impact factor: 11.556

9.  EUS-guided FNA of a portal vein thrombus in hepatocellular carcinoma.

Authors:  Yusuf Kayar; Kenan Ahmet Turkdogan; Birol Baysal; Nurcan Unver; Ahmet Danalioglu; Hakan Senturk
Journal:  Pan Afr Med J       Date:  2015-06-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.